Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$292.1m

Aclaris Therapeutics Future Growth

Future criteria checks 0/6

Aclaris Therapeutics's earnings are forecast to decline at 17% per annum while its annual revenue is expected to grow at 5.5% per year. EPS is expected to decline by 0.1% per annum.

Key information

-17.0%

Earnings growth rate

-0.1%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate5.5%
Future return on equityn/a
Analyst coverage

Good

Last updated23 Dec 2024

Recent future growth updates

Recent updates

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGS:ACRS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268-88-68-835
12/31/202512-62-43-617
12/31/202416-58-17-67
9/30/202427-37-18-18N/A
6/30/202432-59-65-64N/A
3/31/202431-77-74-73N/A
12/31/202331-88-80-78N/A
9/30/202321-115-92-91N/A
6/30/202331-105-75-74N/A
3/31/202331-96-74-73N/A
12/31/202230-87-68-68N/A
9/30/202224-82-66-66N/A
6/30/20226-83-69-68N/A
3/31/20226-81-61-61N/A
12/31/20217-91-52-52N/A
9/30/20217-82-44-44N/A
6/30/20217-71-46-45N/A
3/31/20217-65-44-44N/A
12/31/20206-51-39-39N/A
9/30/20206-57-51-50N/A
6/30/20206-69-63-61N/A
3/31/20204-102-73-72N/A
12/31/20194-114-98-96N/A
9/30/20195-118-105-103N/A
6/30/20195-115-111-110N/A
3/31/20196-79-112-110N/A
12/31/20186-82-102-101N/A
9/30/20185-81-94-92N/A
6/30/20185-79N/A-76N/A
3/31/20183-86N/A-64N/A
12/31/20172-50N/A-55N/A
9/30/20171-57N/A-45N/A
6/30/2017N/A-50N/A-41N/A
3/31/2017N/A-48N/A-40N/A
12/31/2016N/A-48N/A-35N/A
9/30/2016N/A-42N/A-31N/A
6/30/2016N/A-42N/A-31N/A
3/31/2016N/A-33N/A-24N/A
12/31/2015N/A-23N/A-20N/A
9/30/2015N/A-21N/A-19N/A
6/30/2015N/A-13N/A-10N/A
3/31/2015N/A-12N/A-9N/A
12/31/2014N/A-11N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACRS's revenue (5.5% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: ACRS's revenue (5.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACRS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 21:05
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI